Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis

Human Pathology

Volumn 40, Issue 10, 2009, Pages 1418-1426

  Castellvi, Josep ^a   Garcia, Angel ^a   Ruiz Marcellan, Carmen ^a   Hernández Losa, Javier ^a   Peg, Vicente ^a   Salcedo, Mayte ^a   Gil Moreno, Antonio ^a   y Cajal, Santiago Ramon ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

4E BP1; Cell signaling; Endometrial cancer; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69949156862     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.12.019     Document Type: Article

References (38)

1. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., et al. A census of human cancer genes. Nat Rev Cancer 4 (2004) 177-183
2. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
3. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Natarajan M., Lin K.M., Hsueh R.C., Sternweis P.C., and Ranganathan R. A global analysis of cross-talk in a mammalian cellular signalling network. Nat Cell Biol 8 (2006) 571-580
5. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 (1983) 10-17
6. Ellenson L.H., and Wu T.C. Focus on endometrial and cervical cancer. Cancer Cell 5 (2004) 533-538
7. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444 (2004) 213-223
8. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319 (2004) 1-11
9. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
10. Menard S., Pupa S.M., Campiglio M., and Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 22 (2003) 6570-6578
11. Peiro G., Mayr D., Hillemanns P., Lohrs U., and Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 17 (2004) 227-287
12. Santin A.D., Bellone S., Van S.S., et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104 (2005) 1391-1397
13. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6 (2005) 827-837
14. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
15. Hayashi S., Sakamoto T., Inoue A., Yoshida N., Omoto Y., and Yamaguchi Y. Estrogen and growth factor signaling pathway: basic approaches for clinical application. J Steroid Biochem Mol Biol 86 (2003) 433-442
16. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
17. Avdulov S., Li S., Michalek V., et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5 (2004) 553-563
18. Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107 (2006) 1801-1811
19. Rojo F., Najera L., Lirola J., et al. 4E-Binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13 (2007) 81-89
20. Armengol G., Rojo F., Castellvi J., et al. 4E-Binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67 (2007) 7551-7555
21. Mamane Y., Petroulakis E., LeBacquer O., and Sonenberg N. mTOR, translation initiation and cancer. Oncogene 25 (2006) 6416-6422
22. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-930
23. Baak J.P., Van D.B., Steinbakk A., et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol 36 (2005) 555-561
24. Pallares J., Bussaglia E., Martinez-Guitarte J.L., et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 18 (2005) 719-727
25. Hayes M.P., Wang H., Espinal-Witter R., et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12 20 Pt 1 (2006) 5932-5935
26. Mizuuchi H., Nasim S., Kudo R., Silverberg S.G., Greenhouse S., and Garrett C.T. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 52 (1992) 2777-2781
27. Ejskjaer K., Sorensen B.S., Poulsen S.S., Forman A., Nexo E., and Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 104 (2007) 158-167
28. Morrison C., Zanagnolo V., Ramirez N., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24 (2006) 2376-2385
29. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005) 7455-7464
30. Mori N., Kyo S., Sakaguchi J., et al. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis. Cancer Sci 98 (2007) 1881-1888
31. Uegaki K., Kanamori Y., Kigawa J., et al. PTEN-Positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 14 (2005) 389-392
32. McCubrey J.A., Steelman L.S., Chappell W.H., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773 (2007) 1263-1284
33. Mizumoto Y., Kyo S., Mori N., et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 98 (2007) 652-658
34. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12 (1998) 502-513
35. De B.A., and Graff J.R. eIF-4E Expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
36. Rice L.W., Stone R.L., Xu M., et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mullerian tumors. Am J Obstet Gynecol 194 (2006) 1119-1126
37. Constantinou C., and Clemens M.J. Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene (2005)
38. Rong L., Livingstone M., Sukarieh R., et al. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14 (2008) 1318-1327